Literature DB >> 25727999

Medicare Reimbursement Attributable to Periprosthetic Joint Infection Following Primary Hip and Knee Arthroplasty.

Sarah H Yi1, James Baggs1, Steven D Culler2, Sandra I Berríos-Torres1, John A Jernigan1.   

Abstract

This study estimated Medicare reimbursement attributable to periprosthetic joint infection (PJI) across the continuum of covered services four years following hip or knee arthroplasty. Using 2001-2008 Medicare claims data, total and annual attributable reimbursements were assessed using generalized linear regression, adjusting for potential confounders. Within one year following arthroplasty, 109 (1.04%) of 10,418 beneficiaries were diagnosed with PJI. Cumulative Medicare reimbursement in the PJI arm was 2.2-fold (1.9-2.6, P<.0001) or $53,470 ($39,575-$68,221) higher than that of the non-PJI arm. The largest difference in reimbursement occurred the first year (3.2-fold); differences persisted the second (2.3-fold) and third (1.9-fold) follow up years. PJI following hip or knee arthroplasty appears costly to Medicare, with cost traversing several years and health care service areas. Published by Elsevier Inc.

Entities:  

Keywords:  Medicare reimbursement; arthroplasty; healthcare costs; healthcare-associated infection; periprosthetic joint infection

Mesh:

Year:  2015        PMID: 25727999     DOI: 10.1016/j.arth.2015.01.017

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  4 in total

1.  [Anti-infective strategies in trauma surgery Part 1].

Authors:  C Willy; A Trampuz
Journal:  Unfallchirurg       Date:  2017-06       Impact factor: 1.000

2.  Limiting the Surveillance Period to 90 Days Misses a Large Portion of Infections in the First Year After Total Hip and Knee Arthroplasty.

Authors:  Stefano Muscatelli; Huiyong Zheng; Aditya Muralidharan; Viktor Tollemar; Brian R Hallstrom
Journal:  Arthroplast Today       Date:  2022-05-30

3.  Variation in Prosthetic Joint Infection and treatment strategies during 4.5 years of follow-up after primary joint arthroplasty using administrative data of 41397 patients across Australian, European and United States hospitals.

Authors:  Perla J Marang-van de Mheen; Ellie Bragan Turner; Susan Liew; Nora Mutalima; Ton Tran; Sten Rasmussen; Rob G H H Nelissen; Andrew Gordon
Journal:  BMC Musculoskelet Disord       Date:  2017-05-22       Impact factor: 2.362

4.  Are There Benefits In Early Diagnosis Of Prosthetic Joint Infection With Multiplex Polymerase Chain Reaction?

Authors:  Christian Lausmann; Akos Zahar; Mustafa Citak; Julian Brañes; Stefan Schmidl; Lars Frommelt; Thorsten Gehrke; Matthias Gebauer
Journal:  J Bone Jt Infect       Date:  2017-09-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.